Updates on Cytochrome P450-Mediated Cardiovascular Drug Interactions

Cheng, Judy; Frishman, William H.; Aronow, Wilbert S.

doi:10.1097/mjt.0b013e31813e63be

Cited by 20 publications

(12 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A natureza, extensão, e relevância clínica dessas interações medicamentosas, dependem se o fármaco exerce atividade de substrato, indutor e/ou inibidor de enzimas CYP450. 6 As interações medicamentosas decorrentes da inibição de enzimas do CYP450 são mais frequentes que as causadas pela indução enzimática, e geralmente ocorrem quando inibidor e substrato competem diretamente pelo sítio de ligação da enzima. 5,7 A inclusão de indutores do CYP450 no regime terapêutico do paciente pode ter como principal consequência clínica a redução da efetividade de um dos medicamentos.…”

Section: Resumo Revista Médica De Minas Geraisunclassified

Drugs with activity on the cytochrome P450 used by elderly at home

Braz¹,

Figueiredo²,

Barroso³

et al. 2018

Revista Médica De Minas Gerais

View full text Add to dashboard Cite

Section: Resumo Revista Médica De Minas Geraisunclassified

Drugs with activity on the cytochrome P450 used by elderly at home

Braz¹,

Figueiredo²,

Barroso³

et al. 2018

Revista Médica De Minas Gerais

View full text Add to dashboard Cite

“…The CYP450s constitute a multi-gene family of primarily membrane-associated proteins that are expressed in most organ systems and play important roles in the synthesis and biotransformation of hormones, cholesterol and vitamin D, among others, and are engaged in a large and diverse range of enzymatic activities, including the catalysis of organic substrate oxidation [76][77][78]. Specifically, they constitute the most important metabolizers for anti-lipidemic agents, particularly the HMGCR inhibitors (statins) [79].…”

Section: Influence Of Ethnicity On Patient Response To Anti-lipidemicmentioning

confidence: 99%

Ethnicity and Response to Drug Therapy

Al‐Rasheed¹,

Dzimiri²

2016

Cholesterol Lowering Therapies and Drugs

View full text Add to dashboard Cite

Hypercholesterolemia is a complex disorder presenting in different forms, including the familial form (FH), with varying underlying aetiology, and contributing substantially to coronary artery disease. Particularly, the FH underlies monogenic changes in genes involved in cholesterol synthesis and transport, including the low density lipoprotein receptor, proprotein convertase sublitisin/kexin type 9 and apolipoprotein B. However, hyperlipidemia is largely a complex interaction of changes in multiple genes with environmental factors, such as diet, overweight and obesity that are controllable by adopting healthy eating habits and exercise, which may vary by ethnicity. Diet alone is often not adequate to achieve the desired lipid lowering effect in individuals harbouring very high cholesterol levels, necessitating the use of lipid lowering medication or other forms of therapy. Antilipidemic drugs fall into (a) bile acid sequestrants (b) cholesterol absorption inhibitors, (c) 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, (d) fibric acid derivatives (e) proprotein convertase subtilisin/kexin type 9 inhibitors, (f) miscellaneous agents and (g) drug combinations. Mutations in their various metabolizing enzymes, particularly the cytochrome P450 family, often lead to partially/non-functional, or even rapid metabolizing phenotypes, triggering great variations in the way individuals respond to drug therapy, which in turn depends on ethnicity. This may produce unexpected outcomes such as therapeutic failure, adverse side effects and toxicity in individuals of different ethnic origin. Hence, in-depth information of the impact of ethnicity on these relationships has the huge potential of achieving optimal quality use of drugs as well as improving the efficacy and safety of antilipidemic therapeutic agents.

show abstract

“…Es existiert eine Reihe bekannter und kli nisch relevanter Interaktionen, die früher nicht oder nur unvollständig erklärbar waren [1,2,3,4,5,7,14,15,16,17,18,23] [23,26,29]. Auch die Anzahl der Arbeiten, die sich mit Interaktionen in der Intensivmedizin befassen, ist gering [16,27].…”

Section: Wechselwirkungen Mit Transporternunclassified

“…29% erhöht. Obwohl keine direkte Auswirkung auf die Blut gerinnung beobachtet wurde, wird zu einer Überprüfung der INR bei gleich zeitiger Gabe geraten [5]. Der Mechanis mus dieser möglichen Interaktion ist un bekannt.…”

Section: Tigecyclinunclassified

See 1 more Smart Citation

Clinically relevant pharmacokinetic drug interactions in the intensive care unit

Kammerer

2012

Med Klin Intensivmed Notfmed

View full text Add to dashboard Cite

Critically ill patients in the intensive care unit (ICU) are predisposed to pharmacokinetic drug interactions because of the complexity of the drug regimens received in the intensive care setting. Drugs may affect the absorption, distribution, metabolism and/or elimination of an object drug and consequently alter the intended pharmacologic response and potentially lead to an adverse event. The paper presents an overview of pharmacokinetic drug-drug interactions which can occur with commonly used drugs in the ICU and outlines the underlying types and mechanisms.

show abstract

Updates on Cytochrome P450-Mediated Cardiovascular Drug Interactions

Cited by 20 publications

References 73 publications

Drugs with activity on the cytochrome P450 used by elderly at home

Drugs with activity on the cytochrome P450 used by elderly at home

Ethnicity and Response to Drug Therapy

Clinically relevant pharmacokinetic drug interactions in the intensive care unit

Contact Info

Product

Resources

About